Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleGout

Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation

Lisa K. Stamp, Anne Horne, Jill Drake, Borislav Mihov, Janine Haslett, Christopher Frampton and Nicola Dalbeth
The Journal of Rheumatology November 2026, 53 (11) 1268-1271; DOI: https://doi.org/10.3899/jrheum.2026-0389
Lisa K. Stamp
1L.K. Stamp, MBChB, PhD, J. Drake, BN, J. Haslett, BN, University of Otago, and Health New Zealand, Christchurch;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lisa K. Stamp
  • For correspondence: lisa.stamp{at}cdhb.health.nz
Anne Horne
2A. Horne, MBChB, B. Mihov, University of Auckland, Auckland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill Drake
1L.K. Stamp, MBChB, PhD, J. Drake, BN, J. Haslett, BN, University of Otago, and Health New Zealand, Christchurch;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Borislav Mihov
2A. Horne, MBChB, B. Mihov, University of Auckland, Auckland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janine Haslett
1L.K. Stamp, MBChB, PhD, J. Drake, BN, J. Haslett, BN, University of Otago, and Health New Zealand, Christchurch;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Frampton
3C. Frampton, PhD, University of Otago, Christchurch;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Dalbeth
4N. Dalbeth, MBChB, MD, University of Auckland, and Health New Zealand, Auckland, New Zealand.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicola Dalbeth
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective Current prescribing recommendations support higher doses of allopurinol in tophaceous gout to accomplish full control of gout and to lower serum uric acid to normal or near-normal levels. The aim of this study was to determine whether outcomes differ between individuals with and without tophi during 1 year of allopurinol prescribed according to a serum urate (SU) target.

Methods Individual-level participant data from 2 randomized trials of gout (n = 383) were analyzed. Both trials used a treat-to-target strategy with allopurinol and an SU target of < 0.36 mmol/L. The primary outcome was the percentage of participants at target-level SU at month 12 among those with and without tophi. Secondary outcomes included the absence of gout flares. The percentages of participants with target-level SU and the absence of gout flares were compared between those with and without baseline tophi using the Cochran-Mantel-Haenszel test, controlling for study.

Results Most participants were male, were of European ethnicity, and had longstanding gout. Tophi were present in 33% of participants. There was no statistically significant difference in the percentage of participants with target-level SU at 12 months between those with and without tophi (70.3% vs 73.6%; P = 0.76) nor in the percentage of participants without gout flares during the month before month 12 between those with and without tophi (71.4% vs 79.7%; P = 0.27).

Conclusion Despite the higher monosodium urate crystal burden in those with tophi, key gout outcomes, including urate-lowering efficacy and absence of gout flares, did not differ from those without tophi when allopurinol was prescribed.

Key Indexing Terms:
  • gout
  • tophi
  • urate-lowering therapy
  • Accepted for publication June 24, 2026.
  • Copyright © 2026 by the Journal of Rheumatology
View Full Text

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology: 53 (11)
The Journal of Rheumatology
Vol. 53, Issue 11
1 Nov 2026
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation
Lisa K. Stamp, Anne Horne, Jill Drake, Borislav Mihov, Janine Haslett, Christopher Frampton, Nicola Dalbeth
The Journal of Rheumatology Nov 2026, 53 (11) 1268-1271; DOI: 10.3899/jrheum.2026-0389

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation
Lisa K. Stamp, Anne Horne, Jill Drake, Borislav Mihov, Janine Haslett, Christopher Frampton, Nicola Dalbeth
The Journal of Rheumatology Nov 2026, 53 (11) 1268-1271; DOI: 10.3899/jrheum.2026-0389
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Keywords

GOUT
TOPHI
URATE-LOWERING THERAPY

Related Articles

Cited By...

More in this TOC Section

  • Effectivity and Safety of Febuxostat in Reducing Serum Urate in Gout Patients With Chronic Kidney Disease: A Prospective Multicenter ULTRA Registry Study
  • Do Monosodium Urate Crystals Reduce at Different Rates in Joints and Tendons During Urate-Lowering Therapy? A Dual-Energy Computed Tomography Study
Show more Gout

Similar Articles

Keywords

  • gout
  • tophi
  • urate-lowering therapy

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire